宫内生物制剂暴露的婴儿长期结局:妊娠炎症性疾病新生儿结局登记结果
该前瞻性队列纳入438名随访至少4年的IBD孕妇子代,比较不同药物暴露下严重感染、先天畸形和发育迟缓的发生率。未观察到不同药物间不良结局的差异,早产而非特定药物暴露与感染风险相关,母乳喂养与严重感染差异无关。结果支持整个孕期使用有效的IBD治疗。
要点
- 宫内暴露于IBD治疗药物未增加子代严重感染、先天畸形或发育迟缓风险
- 早产与子代感染风险相关,而非特定药物暴露
- 母乳喂养与严重感染差异无关
核心结论
- 宫内暴露于IBD治疗药物未观察到子代不良结局差异,支持孕期使用有效IBD治疗。
研究设计与样本
- 前瞻性队列研究,纳入妊娠IBD女性及其子代(妊娠IBD与新生儿结局登记),共438名随访至少4年的子代。
主要发现
- 按药物暴露比较,严重感染、先天畸形和发育迟缓的发生率无差异。
- 早产与感染风险相关,但特定药物暴露与感染风险无关。
- 母乳喂养与严重感染差异无关。
临床怎么用
- 临床应支持整个孕期使用有效的IBD治疗,无需因担心子代长期不良结局而停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Long-term data are needed for offspring exposed in utero to medications for inflammatory bowel disease (IBD). METHODS: We used a prospective cohort of pregnant women with IBD and their offspring (Pregnancy in IBD and Neonatal Outcomes) to compare rates of serious infection, congenital malformations, and developmental delay by medication exposures. RESULTS: We included 438 offspring with at least 4 years of follow-up. No differences in adverse outcomes were observed by medication. Preterm birth, but not specific drug exposure, was associated with infection risk. Breastfeeding was not associated with serious infection differences. DISCUSSION: These findings support the use of effective IBD therapies throughout pregnancy.
引用
- Kohli A, Long MD, Beaulieu DB, et al. Long-Term Infant Outcomes After In Utero Biologic Exposure: Results From the Pregnancy Inflammatory Disease Neonatal Outcomes Registry. Am J Gastroenterol. 2026. PMID: 41789805. doi:10.14309/ajg.0000000000003991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。